Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04197999 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04197999: Clinical Trial Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT04197999 is a Phase 1 study that was terminated before completion, run by GlycoMimetics Incorporated. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04197999, a Phase 1 study, was terminated before completion, sponsored by GlycoMimetics Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.
Interventions
- DRUG GMI-1359
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-11-21 |
| Est. Completion | 2021-08-25 |
| Phase | Phase 1 |
Why NCT04197999 stopped before completion
NCT04197999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which GMI-1359 is the first listed.
NCT04197999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04197999 about?
NCT04197999 is a clinical study titled "A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer". This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.
What is the current status of trial NCT04197999?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-11-21. Estimated completion is 2021-08-25.
What interventions are being tested in trial NCT04197999?
The interventions under investigation include: GMI-1359 (DRUG).
Who is sponsoring clinical trial NCT04197999?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04197999's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI